Optimizing the Balance Between High Dose & Mitigating Toxicity to Maintain Successful Expression in the Muscle
Returning to Boston in April 2022 as its first in-person event, the 2nd Gene Therapy for Muscular Disorders Summit is the field’s only industry-focused event specifically designed to help gene therapy developers successfully target the muscle.
With a disease-agnostic agenda, but highlighting novel research in Duchenne’s (DMD), Limb-Girdle (LGMD), Pompe Disease and X-Linked Myotubular Myopathy (XLMTM), the expert industry speakers from the likes of Solid Biosciences, Sarepta Therapeutics, Astellas Gene Therapies and Pfizer will spend 4-days discussing the fields hottest topics from navigating toxicity to state-of-the-art muscular targeting.
Your Expert Speakers Include:
Health & Safety
The health, safety and well-being of our community remains our highest priority. Therefore, all attendees will be required to complete a health declaration prior to attending the event. As part of this, attendees must declare that they are either fully vaccinated and /or have completed a negative Lateral Flow Test or PCR Test within 48 hours the event*. For further information around Health and Safety onsite, please visit our FAQ here.
*Please note, this is subject to change at any time without prior notice.
New for 2022:
Content: Address the opportunities and challenges facing cardiac muscle targeting
First In-Person Event: Make the most of your opportunity to catch up with familiar faces and make new connections in the muscular disorders field
New Companies: Discover and meet new speakers and companies to improve your understanding of the gene therapy landscape with muscular pipelines
Post-Conference Vector Innovation Day: Take part in the vector day for a more in-depth discussion to optimize vectors targeting the muscle
Who Attended in 2021?
Hear What Our Audience Say
“Fantastic opportunity to learn from the experts!”
Karin Lucas, Associate Director, Sarepta Therapeutics
“The conference overall expanded my knowledge in gene therapy targeting muscle diseases but also offered additional learning in the areas of immunology and redosing strategies.”
Paul Fitzpatrick, Senior Director - Bioprocess Technology, Zogenix Inc
“Being new to the space this was a great opportunity to learn about the relevant areas for developing gene therapies in muscle”
Lori Getts, Vice President - Preclinical & Process Development, Code Biotherapeutics